These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 36445478)

  • 1. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
    Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
    Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
    Davern M; Donlon NE; O' Connell F; Sheppard AD; Hayes C; King R; Temperley H; Butler C; Bhardwaj A; Moore J; Bracken-Clarke D; Donohoe C; Ravi N; Reynolds JV; Maher SG; Conroy MJ; Lysaght J
    Transl Oncol; 2022 Jun; 20():101406. PubMed ID: 35366537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
    Davern M; Gaughan C; O' Connell F; Moran B; Mylod E; Sheppard AD; Ramjit S; Yun-Tong Kung J; Phelan JJ; Davey MG; Ryan EJ; Butler C; Quinn L; Howard C; Tone E; Phoenix E; Butt WT; Lynam-Lennon N; Maher SG; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Donlon NE
    Front Immunol; 2023; 14():1150754. PubMed ID: 37359545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.
    Davern M; Fitzgerald MC; Buckley CE; Heeran AB; Donlon NE; McGrath J; O' Connell F; Deshpande MR; Hayes C; MacDonald J; Sheppard AD; Reynolds JV; Maher SG; Lynam-Lennon N; Murphy B; Lysaght J
    Transl Oncol; 2022 May; 19():101381. PubMed ID: 35245832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
    Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
    Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
    Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
    World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
    Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J
    Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
    Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
    Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia.
    Qiang L; Hong L; Jian X; Zhanlin Z
    Int Immunopharmacol; 2023 May; 118():110010. PubMed ID: 36924563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoints in the tumor microenvironment.
    Toor SM; Sasidharan Nair V; Decock J; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
    Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.